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Objective: To evaluate the effects of infliximab and corticosteroid treatment on the lipid profile in patients with
active rheumatoid arthritis (RA).
Methods: Infliximab infusions were given at weeks 0, 2, 6 and then every 8 weeks. Before each infusion,
disease activity parameters (Disease Activity Index 28-Joint Score (DAS28)) C reactive protein (CRP) and lipid
levels (total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, apolipoprotein A1 (apo A1)
and apolipoprotein B) were measured in 80 consecutive patients with RA, who completed the study period of
48 weeks. Longitudinal analyses were used to investigate (1) the course of lipid levels over a period of time
and (2) the relationship between lipids, prednisone dose and disease activity.
Results: Infliximab treatment causes a significant reduction in disease activity and a concomitant decrease in
prednisone dose. Although they initially improved significantly, all lipid levels had returned to baseline levels
after 48 weeks, except for apo A1. Longitudinal analyses revealed significant yet opposite associations
between lipid levels and disease activity and between lipid levels and prednisone dose. DAS28 improvement
by 1 point was associated with an increase of 0.016 mmol/l (0.618 mg/dl) total cholesterol and
0.045 mmol/l (1.737 mg/dl) HDL-cholesterol. Reduction of 10 mg prednisone was associated with a
decrease of 0.04 mmol/l (1.544 mg/dl) total cholesterol and 0.16 mmol/l (6.177 mg/dl) HDL-cholesterol.
Conclusion: Overall, no changes in serum lipid levels were observed after 48 weeks of infliximab treatment.
The initial beneficial effects of infliximab on the lipid profile, by means of a reduction of disease activity, are
attenuated by a concomitant decrease in prednisone dose.
R
heumatoid arthritis (RA) is a chronic, inflammatory
disorder of the joints. Patients with RA have an increased
morbidity and mortality compared with the general
population. Mortality from cardiovascular disease (CVD) is
the leading cause of death observed in patients with RA.1 This
excess cardiovascular mortality in patients with RA is pre-
dominantly due to accelerated atherosclerosis.2
A well-known cause of atherosclerosis is an atherogenic lipid
profile. In particular, low levels of high-density lipoprotein (HDL)-
cholesterol, and high levels of total cholesterol, low-density
lipoprotein-cholesterol and triglycerides are associated with an
increased prevalence of CVD in the general population.3 An
important prognostic indicator for future CVD is the atherogenic
index,which is the ratio between total cholesterol and HDL-
cholesterol.4 New data indicate that apolipoproteins, which are
protein parts of the lipoprotein complex, are possibly better
predictors for CVD. High levels of apolipoprotein B (apo B) and an
increased apolipoprotein B:apolipoprotein A1 ratio (apo B:apo A1)
are associated with an increased cardiovascular risk, whereas
higher levels of apo A1 are protective for developing CVD.5 6
Several studies reported that RA is associated with an
unfavourable lipid profile, particularly in patients with active
disease.7–9 These studies show that active RA is associated with
lower levels of HDL-cholesterol compared with healthy controls,
leading to a higher—that is, unfavourable—atherogenic index.
Hence, an atherogenic lipid profile may be part of the cause of the
increased cardiovascular risk in patients with RA.
Growing evidence suggests that inflammation in RA is
associated with a worsening of the lipid profile,10 11 which
improves on effective antirheumatic treatment.12 13 We pre-
viously reported that normalisation of the lipid profile in
patients with RA occurred more rapidly in combination
treatment with methotrexate (MTX), sulphasalazine and
prednisone than in treatment with sulphasalazine alone,
thereby demonstrating the temporal relationship between
decreasing disease activity and improvement of the atherogenic
index.14 However, because of the limited duration of the study,
we were unable to answer the question of whether this
difference was due to improved disease suppression or changes
in prednisone dose.
In another study, we found that treatment with anti-tumour
necrosis factor therapy leads to a significant increase of both
total cholesterol and HDL cholesterol levels, which was
inversely related with disease activity. The atherogenic index,
however, remained constant during the 6-week study period.15
Thus far, data regarding lipid changes during immunosup-
pressive treatment are contradictory,16 17 and studies observing
lipid changes during long-term immunosuppressive treatment
are lacking. In the present study, longitudinal analyses were
performed to investigate (1) the longitudinal course of lipid
levels, including apolipoproteins, over time during immuno-
suppressive treatment—that is, infliximab—and (2) the long-
itudinal relationship between lipids and indicators of disease
activity and between lipids and prednisone doses.
PATIENTS AND METHODS
Consecutive patients with active RA (defined as a Disease
Activity Index 28-Joint Score (DAS28) of at least 3.2) who were
referred to the Slotervaart Hospital, Amsterdam, The
Netherlands, for treatment with infliximab were included. All
patients with RA fulfilled the American College of
Abbreviations: apo A1, apolipoprotein A1; apo B, apolipoprotein B;
CVD, cardiovascular disease; DAS28, Disease Activity Index 28-Joint
Score; GEEs, general estimation equations; HDL, high-density lipoprotein;
RA, rheumatoid arthritis; MTX, methotrexate
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Rheumatology criteria.18 Infusions with infliximab were given
at weeks 0, 2, 6 and 14 weeks, and from thereon every 8 weeks.
Generally, infliximab was given in combination with stable
doses of MTX. Infliximab was administered intravenously at a
starting dose of 3 mg/kg. In patients with inadequate response,
as judged by the patients’ rheumatologist, the dose of
infliximab could be increased to 7.5 mg/kg. Blood samples
(non-fasting) were collected in the morning, before each
infusion at weeks 0, 6, 22 and 48 and were stored at –70 C˚
until analyses. Total cholesterol, HDL-cholesterol, triglycerides,
apo A1 and apo B concentrations were measured and the total
cholesterol/HDL cholesterol and apo B:apo A1 ratios were
calculated. At each visit disease activity, defined as DAS28,19
and drug treatment were assessed. In all, 108 patients were
included in the cohort, but 28 patients dropped out in the first
year of treatment: 22 (78.5%) because of non-response, 5 (18%)
because of side effects and 1 (3.5%) patient who died owing to
unrelated events. Thus, the data from 80 patients were eligible
for analyses. The baseline characteristics of the dropout patients
were comparable to those of the patients included in the study
(data not shown). Thus, all included patients completed the
study period of 48 weeks and the patients who dropped out
(n = 28) were not included for the analysis. There were no
(additional) exclusion criteria.
Lipids
Total serum cholesterol (,5.0 mmol/l (193 mg/dl)) and triglycer-
ides (,2.2 mmol/l, 196 mg/dl)) were measured by an enzymatic
method using Roche clinical chemistry analysers. HDL-cholesterol
(men, .0.9 mmol/l (35 mg/dl)); women, .1.1 mmol/l (42 mg/
dl)) was determined enzymatically with polyethylene glycol-
modified enzymes. The atherogenic index was calculated using
the following formula: atherogenic index = total/HDL-cholesterol.
Apo A1 (men, 1.04–2.02 g/l; women, 1.08–2.25 g/l) and apo B
(men, 0.66–1.33 g/l; women, 0.60–1.17 g/l) were analysed by an
immunoturbidimetric method, using assays supplied by Roche
Diagnostics (Basel, Switzerland).
As it was expected that only small differences in the
concentration of analyses could be significant, collected sera were
first stored frozen and subsequently analysed on the same day in a
single run, with all sera belonging to one person grouped together.
This set-up produces within-group analytical coefficients of
variation for the analyses in their reference range of ,1%.
Statistical analyses
As some patients were treated with prednisone, differences in
lipid profiles between prednisone users (yes/no) were analysed by
using independent t tests for normally distributed variables (ie,
HDL-cholesterol, apo A1, apo B and the apo B:apo A1 ratio), and
Mann–Whitney U tests for not normally distributed variables (ie,
total cholesterol, atherogenic index and triglycerides).
The time course of lipid levels during treatment with
infliximab was investigated by using general estimation
equations (GEEs). This regression technique was used as it
adjusts for dependency of several measurements within one
subject and is capable of dealing with unequally spaced time
intervals and with missing data.20 For this analysis, each lipid
value was included separately as a dependent variable and time
was included as a categorical independent variable.
GEE analyses were also used to investigate the influence of
indicators of disease activity (ie, DAS28 score and C reactive
protein (CRP)) and prednisone dose on all lipid levels. Hence,
we performed two analyses: (1) GEE analyses including a lipid
value and an indicator of disease activity or prednisone dose:
for example, total cholesterol as a dependent variable and
DAS28 as an independent variable, total cholesterol as a
dependent variable and CRP as an independent variable, and
total cholesterol as a dependent variable and prednisone as an
independent variable. (2) GEE analyses including a lipid value
and an indicator of disease activity corrected for prednisone
dose. With GEE analyses, the development of a certain lipid is
associated with the development of disease activity or
prednisone dose, resulting in one regression coefficient. All
analyses were adjusted for age and gender. As the distributions
of total cholesterol, atherogenic index and triglycerides were
not normal, a log transformation was performed before the
GEE analyses. All analyses were performed with STATA V.7 and
p values ,0.05 were considered significant.21
RESULTS
Patients
The study population consisted of 80 (62 women and 18 men)
consecutively included patients with RA with a mean (SD) age
of 56 (14) years. The median disease duration was 10 (range
0–59) years; 55 (69%) patients were IgM-rheumatoid factor
positive and 67 (82%) patients had erosions. At baseline, statins
were used by 4 (5%) patients and diabetes mellitus was
reported by 2 (2%) patients. During the study period, none of
the included patients started statins or glucose-lowering
treatment. In all, 77 (96%) patients used concomitant MTX at
a stable dose—that is, 15 mg/week at all time points—and 35
(44%) patients used prednisone at the start of the study (mean
prednisone dose 8.3 mg/day). As expected, treatment with
infliximab leads to a significantly better DAS28-score at
48 weeks compared with baseline: 5.7 vs 3.9 (p,0.01).
Lipids
Table 1 shows the course of lipid levels over time during
treatment with infliximab. Patients who used prednisone had
higher total cholesterol and HDL-cholesterol levels and a lower
atherogenic index at baseline, but these differences did not
reach statistical significance.
After 6 weeks of treatment with infliximab, total cholesterol
levels increased by 6.1% (p,0.01) and HDL-cholesterol levels
increased by 10.3% (p,0.01), resulting in a 6.4% decrease of the
atherogenic index (p,0.01). In the next period (6–22 weeks) both
total cholesterol and HDL-cholesterol levels decreased, but
remained significantly increased compared with baseline. At
48 weeks, total cholesterol and HDL-cholesterol levels approached
baseline levels. As total cholesterol and HDL-cholesterol levels
moved towards baseline levels, the atherogenic index revealed no
significant difference compared with the baseline index at 22 and
48 weeks. Triglycerides levels did not change during the whole
treatment period.
Compared with baseline, apo A1 levels increased by 4.5% at
48 weeks (p,0.01), whereas apo B levels and the apo B:apo A1
ratio did not change significantly at 48 weeks compared with
baseline.
Lipids and disease activity
The course of lipids over time was compared with the course of
disease activity after adjustment for age and gender (table 2). GEE
analyses yielded a significant inverse association between disease
activity and lipid levels. Changes in disease activity (DAS28) were
significantly related with changes in HDL-cholesterol and total
cholesterol levels. This means that if disease activity according to
DAS28 decreases by 1 point, total cholesterol will raise
0.016 mmol/l (0.618 mg/dl) and HDL-cholesterol will increase
by 0.045 mmol/l (1.737 mg/dl), resulting in a more favourable,
that is, lower, atherogenic index. Similarly, the individual
inflammation parameter CRP was significantly inversely asso-
ciated with both HDL-cholesterol and total cholesterol levels.
Moreover, the analyses showed that disease activity was inversely
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related with apo A1, resulting in a lower, that is, more favourable,
apo B:apoA1 ratio.
Lipids and prednisone
During treatment with infliximab, lipid levels were compared
with changes in prednisone dose at different time points after
adjustment for age and gender (table 2). Changes in prednisone
dose were related to changes in HDL-cholesterol and total
cholesterol. Prednisone changes, however, had a greater
influence on HDL-cholesterol than on total cholesterol levels,
resulting in an inverse association between prednisone dose
and the atherogenic index. In other words, a higher prednisone
dose is associated with a lower, that is, more favourable
atherogenic index. Furthermore, the prednisone dose seemed to
have a significant positive relationship with apo A1, leading to a
significant inverse association with the apo B:apo A1 ratio.
The reported associations between lipids and disease activity
and between lipids and prednisone did not change when both
prednisone and disease activity parameters were included as
independent variables in the same regression analysis (data not
shown).
Because of the favourable effect of infliximab on the DAS28
score, the prednisone dose was gradually decreased from a
median dose of 8.3 to 4.6 mg/day. Subgroup analysis revealed
no significant differences with regard to cholesterol levels
between patients with RA with prednisone and without
prednisone at all time points.
DISCUSSION
In this study, we observed a significant increase of total
cholesterol and HDL-cholesterol levels after 6 weeks of inflix-
imab treatment, which gradually returned to baseline after
48 weeks. As a result, improvement of the atherogenic index at
6 weeks was not observed from 22 weeks onwards.
Longitudinal data analyses—that is, GEE analyses—revealed
that lowering the prednisone dose attenuated the effects of
infliximab on total cholesterol and HDL-cholesterol levels and
its main protein part apo A1, thereby abolishing the improve-
ment of the atherogenic index and the apo B:apo A1 ratio.
Nevertheless, apo A1 levels remained significantly increased
after 48 weeks of treatment, which might be important as
accumulating epidemiological evidence indicates that high
levels of apo A1 are strongly related with a lower risk for
future CVD.5 6
Recent research has shown that systemic inflammation plays a
pivotal role in the development of atherosclerosis. Immune cells
dominate early atherosclerotic lesions, their effector molecules
accelerate progression of the lesions and inflammation elicits
CVD.22 Hence, inflammation might be the key to explaining the
enhanced cardiovascular risk in patients with RA.23 Moreover,
inflammation induces the acute-phase response leading to lipid
changes and alterations in lipoprotein metabolism. Most of these
changes—that is, decreased levels of HDL-cholesterol and apo
A1—are pro-atherogenic and ultimately may contribute to the
increased cardiovascular risk in RA. In this study, a decreasing
disease activity resulted in a lower, atherogenic index as a result
of higher total cholesterol levels and even more pronounced
higher HDL levels. In addition, a decrease of disease activity led
to a better apo B:apo A1 ratio, because of significantly increased
apo A1 levels. These findings are in line with other studies
reporting an inverse association between inflammatory markers
(erythrocyte sedimentation rate and CRP) and HDL-cholesterol
or its apo A1.12 13
Differences reported in this study are small and may
therefore question their clinical relevance. Several studies,
however, highlight the importance of lipid changes even
though the observed differences are small. The Lipid Research
Clinics Coronary Primary Prevention Trial and the Framingham
Study, for example, show that a 0.026 mmol/l (1 mg/dl)
increment of baseline HDL-cholesterol is associated with an
approximately 3.5% risk reduction for coronary heart dis-
ease.24 25 Another study performed by Rubins et al26 revealed
that a 6% increase in HDL-cholesterol is associated with an
absolute risk reduction of 4.4% of death from coronary heart
disease or non-fatal infarction. Although these findings cannot
be directly extrapolated to our study, they show the clinical
importance of only small lipid changes. Moreover, several
recent observations indicate that apo-B and apo A1 may in fact
Table 1 Total cholesterol, high-density lipoprotein- cholesterol, triglycerides (mmol/l), apolipoprotein A1 (apo A1), apolipoprotein
B (apo B; g/l) and the atherogenic index and apo B/apo A-1 ratio during treatment with infliximab
Variable Baseline 6 weeks 22 weeks 48 weeks
Median (range) total cholesterol (mmol/l) 4.79 (2.70–8.10) 5.08 (2.79–9.18)* 4.94 (2.90–10.42)* 4.81 (3.21–7.29)
Mean (SD) HDL-cholesterol (mmol/l) 1.46 (0.50) 1.61 (0.54)* 1.55 (0.53)* 1.53 (0.51)
Median (range) atherogenic index 3.42 (1.74–7.78) 3.20 (1.59–8.63)* 3.43 (1.67–8.08) 3.38 (1.62–10.70)
Median (range) triglycerides (mmol/l) 1.26 (0.62–4.40) 1.39 (0.52–3.80)* 1.32 (0.46–3.36) 1.26 (0.62–3.48)
Mean (SD) apo A1 (g/l) 1.58 (0.35) 1.70 (0.33)* 1.65 (0.33)* 1.65 (0.33)*
Mean (SD) apo B (g/l) 0.93 (0.23) 0.95 (0.24) 0.94 (0.24) 0.93 (0.19)
Mean (SD) apo B:Apo A1 ratio 0.62 (0.20) 0.58 (0.20)* 0.59 (0.18) 0.59 (0.16)
apo B:apo A1, apolipoprotein B:apolipoprotein A1 ratio; HDL, high-density lipoprotein.
*p,0.05 Compared with baseline (performed by general estimation equation analyses).
Table 2 Relationship between lipid items, indicators of disease activity and prednisone
Variable
Atherogenic index
Total cholesterol
(mmol/l)
HDL-cholesterol
(mmol/l) Apo B:Apo A1 Apo B (g/l) Apo A1 (g/l)
Coefficient (SE) Coefficient (SE) Coefficient (SE) Coefficient (SE) Coefficient (SE) Coefficient (SE)
Indicators of disease activity
1-point decrease/difference of DAS28 –0.016 (0.008)* 0.016 (0.005)* 0.045 (0.013)* –0.013 (0.005)* 0.004 (0.004) 0.036 (0.009)*
10-points decrease/difference of CRP –0.026 (0.001)* 0.024 (0.001)* 0.067 (0.001)* –0.014 (0.001)* 0.009 (0.001) 0.045 (0.001)*
Reduction/difference of 1 mg prednisone 0.009 (0.004)* –0.004 (0.002)* –0.016 (0.006)* 0.005 (0.002)* 0.001 (0.002) –0.009 (0.004)*
CRP, C reactive protein; DAS28, Disease Activity Index 28-Joint Score; HDL, high-density lipoprotein.
Values are given as regression coefficients (SE), and standard errors estimated by general estimation equation analyses for each lipid item as a continuous outcome
variable. All analyses were adjusted for age and gender.
*p,0.05.
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be more powerful predictors of risk for CVD than the conventional
lipid values.5 6 22 27 This is important and might be clinically
relevant, as this study indicates that apo A1 remains significantly
increased during the whole treatment period.
Mechanisms underlying the decrease of HDL-cholesterol
during inflammation are not firmly established. Our findings,
however, suggest that alterations in prednisone dose are
relevant. We showed that lowering the prednisone dose results
in a decrease of total cholesterol levels that is predominantly
due to a decrease in HDL-cholesterol leading to a higher
atherogenic index (as the effect on total cholesterol was less
pronounced). By contrast, increasing the prednisone dose
might have favourable effects on the lipid profile.
Nevertheless, it is highly uncertain whether or not this
postulated beneficial effect is ultimately offset by other
cardiovascular side effects of long-term prednisone use, such
as insulin resistance and hypertension.
In addition to a previous study performed by our study
group,14 the present study reveals additional insights into the
influence of prednisone and disease activity on the lipid profile
as both have a significant, but opposing, and more pronounced
influence on HDL-cholesterol than on total cholesterol.
MTX may provide a substantial survival benefit, largely by
reducing mortality from CVD.28 Patients in our investigation
were taking stable MTX doses during the treatment period.
Hence, we were not able to evaluate the effect of MTX on the
lipid profile. Our results, however, do indicate that suppression
of inflammation leads to a more favourable lipid profile, which
may also be conceivable for MTX.
There might be additional explanations for the observed
longitudinal lipid changes. First, exercise increases HDL-choles-
terol in healthy individuals,29 and immunosuppressive treatment
is associated with a substantial clinical improvement whereby
patients with RA will increase their physical activity. Second,
patients with RA with a high disease activity have higher levels of
tumour necrosis factor (TNF), which is associated with rheuma-
toid cachexia.30 Treatment with infliximab obviously leads to
lower levels of the TNF, therefore possibly leading to a better
dietary intake resulting in increased lipid levels. Finally, we have
to consider the possibility that the observed lipid changes are a
direct effect of biologicals through blocking TNFa.
In conclusion, the present investigation shows that immu-
nosuppressive treatment with infliximab might have beneficial
effects on the increased cardiovascular risk in patients with RA
via several mechanisms: (1) because of its anti-inflammatory
effects; (2) indirectly as a cause of lower prednisone doses; and
(3) through a small, anti-atherogenic effect on the lipid profile.
Prospective cardiovascular outcome studies are needed to
establish whether or not immuno-suppressive treatment indeed
results in a lower cardiovascular risk.
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